期刊
INVESTIGATIONAL NEW DRUGS
卷 31, 期 6, 页码 1626-1627出版社
SPRINGER
DOI: 10.1007/s10637-013-0023-z
关键词
Solitary fibrous tumor; Soft tissue sarcoma; Sorafenib; Antiangiogenic treatment
资金
- Institut National du Cancer (PHRC)
- Bayer HealthCare France
Malignant solitary fibrous tumors are rare soft-tissue sarcomas. They are considered as low-grade malignancies, but may display metastatic potential in 20 % of the cases. In case of metastatic or locally advanced, unresectable disease, standard treatments, like anthracycline-based regimens, are poorly effective. Previous studies suggested that antiangiogenic drugs, such as sorafenib, could be efficient to treat vascular sarcomas and solitary fibrous tumors. Five patients with progressive SFT were included in this phase 2 study, and treated with sorafenib at a dose of 800 mg daily. Two patients out of the five achieved a 9 months disease control with sorafenib, while their disease had progressed within the month preceding their inclusion. Consequently, our data suggest a potential efficacy of sorafenib in SFT, Further investigation is needed to confirm these data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据